Aspen Pharmacare Holdings Limited (APNHY)
Chart Events
Performance Outlook
| Previous Close | 9.58 |
| Open | 9.58 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 9.58 - 9.58 |
| 52 Week Range | 7.77 - 18.79 |
| Volume | |
| Avg. Volume | 703 |
| Market Cap | 4.36B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 11.97 |
| EPS (TTM) | 0.80 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.17 (1.81%) |
| Ex-Dividend Date | Sep 22, 2021 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APNHY
Related Research
- ASPEN PHARMACARE HLDGS UNSP ADRAnalyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.RatingFair ValueEconomic Moat11 days agoMorningstar
- Reuters
UPDATE 1-Africa CDC hopeful Aspen will get COVID vaccine orders
Africa's top public health body said on Thursday it was hopeful South African pharmaceutical firm Aspen Pharmacare would get orders for its own brand COVID-19 vaccine. Africa Centers for Disease Control and Prevention (CDC) said last month that it is in detailed discussions with buyers to generate demand for Aspen's COVID-19 vaccine Aspenovax. Just one fifth of adults in Africa are fully vaccinated against COVID-19, but demand has fallen across the continent which already receives donated vaccines from Western countries and has supplies to hand from earlier purchases.
- Reuters
UPDATE 1-Aspen COVID vaccine lines risk going idle as J&J orders dwindle
South Africa's Aspen Pharmacare's COVID-19 vaccine production lines may soon go idle, and without any new orders it could be forced to pivot to manufacturing other products, a senior executive said on Wednesday. Aspen currently produces vaccines for Johnson & Johnson and, in March, it struck a deal to produce, price, and sell its own-brand version of the shot for African markets. Aspen has had no orders for its Aspenovax vaccine, and it is not possible to predict future J&J demand, Stavros Nicolaou, Aspen Group Senior Executive, told Reuters, leaving the future of its 450-million-dose annual production capacity in doubt.
- Reuters
S.Africa's Aspen to halt COVID vaccine output as J&J orders dry up
South Africa's Aspen Pharmacare will stop making COVID-19 vaccines from the end of this month due to a lack of orders, a senior executive said, further undermining Africa's already meager capacity to produce doses. Aspen currently produces vaccines for Johnson & Johnson .
